San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Skin Res Technol. 2021 Sep;27(5):810-813. doi: 10.1111/srt.13025. Epub 2021 Mar 2.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, xerosis, and skin barrier dysfunction. Skin barrier alteration is associated with an increase in trans-epidermal water loss (TEWL) and reduction in skin hydration. Dupilumab is a monoclonal antibody targeting interleukin-13 modulating pro-inflammatory signal transduction, which has been approved for moderate to severe AD. The aim of this study is to evaluate the effects of Dupilumab on skin barrier functions, using non-invasive instruments and clinical evaluation.
Thirty patients affected by moderate-severe AD, who had been administered dupilumab, were evaluated by clinical examination and through the instrumental measurements of TEWL and corneometry at the baseline (T0) and 8 weeks (T1) on lesional skin. The clinical evaluation was performed using the Eczema Area and Severity Index (EASI) score. Moreover, a Dermatology Life Quality Index (DLQI) and 7-day numeric rating scale (NRS) questionnaires were administered to each patient.
The instrumental parameters of skin barrier recovery confirmed the clinical improvement outcomes with a statistically significant reduction of TEWL at T1.
Our data confirm the clinical outcomes already reported in the literature and show that there was an inverse proportional correlation between TEWL levels and clinical severity after 8 weeks of treatment with dupilumab.
特应性皮炎（AD）是一种慢性炎症性皮肤病，其特征为瘙痒、干燥和皮肤屏障功能障碍。皮肤屏障改变与经表皮水分流失（TEWL）增加和皮肤水合作用降低有关。度普利尤单抗是一种针对白细胞介素-13 的单克隆抗体，可调节促炎信号转导，已被批准用于中重度 AD 的治疗。本研究旨在使用非侵入性仪器和临床评估来评估度普利尤单抗对皮肤屏障功能的影响。
30 名患有中重度 AD 的患者接受了度普利尤单抗治疗，在基线（T0）和 8 周（T1）时对皮损皮肤进行了临床检查和 TEWL 及皮肤角质层水分测量仪（corneometry）的仪器测量。临床评估采用 Eczema Area and Severity Index（EASI）评分进行。此外，每位患者还填写了 Dermatology Life Quality Index（DLQI）和 7 天数字评分量表（NRS）问卷。
皮肤屏障恢复的仪器参数证实了临床改善的结果，TEWL 在 T1 时显著降低。
我们的数据证实了文献中已经报道的临床结果，并表明在接受度普利尤单抗治疗 8 周后，TEWL 水平与临床严重程度呈反比关系。
